Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 16/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAP2K7 | O14733 | 6/20 | 0.48 |
| ▸ | SGK1 | O00141 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969461 | 0.90 | MEN1 (0.53) | MAP2K4MAPTSGK1KDM4EALDH1A1 | |
| SCHEMBL3971235 | 0.90 | SGK1 (0.56) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3970942 | 0.90 | MAP2K4 (0.56) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3964176 | 0.89 | SGK1 (0.52) | MAP2K4MAPTSGK1KDM4EALDH1A1 | |
| SCHEMBL3967746 | 0.88 | MAP2K4 (0.55) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3964181 | 0.85 | SGK1 (0.57) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3967980 | 0.85 | MAP2K4 (0.62) | MAP2K4MAP2K7 | |
| SCHEMBL3962444 | 0.85 | SGK1 (0.61) | MAP2K4SGK1 | |
| SCHEMBL3964290 | 0.84 | ALDH1A1 (0.53) | MAP2K4MAPTSGK1KDM4EALDH1A1 | |
| SCHEMBL3966356 | 0.84 | PKM (0.56) | MAP2K4SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101243051-A | P38 MAP kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | CN | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | MAP2K4 101/4885MAPT 1517/4885MAP2K7 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.